fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

The Fed’s Jackson Hole Moves Boost Stocks To End The Week – $AAPL $EPRX $LTRN $MODD $NVDA $SBUX $TSLA Rise!

By John F. Heerdink, Jr.

As markets eagerly anticipated Federal Reserve Chair Jerome Powell’s speech at the Jackson Hole symposium, U.S. stock indices closed the week ending August 23, 2024, with modest gains on the high end of the market and outside gains on the lower end, reflecting investor optimism about potential interest rate cuts and the economic outlook.

Stock Market Weekly Gains

Major U.S. stock indices posted solid gains for the week, with the S&P 500 up 1.4% and Dow Jones Industrial Average up 1.3%, while the Nasdaq Composite also rose 1.4%. The MSCI EAFE index, representing international developed markets, outpaced domestic indices with a 1.7% increase. These gains helped offset earlier losses in the week, as investors became confident that rates will be cut soon after Jerome Powell’s Jackson Hole speech confirmed as much. This week the yield curve pulled substantially as the 10-yr note yield fell 8 basis points to 3.81% & the 2-yr note yield dropped 16bps lower closing at 3.91%, while crude oil prices decreased -.8% to $74.90 per barrel. The small caps on the Russell 2000 closed at 2,218.70 (+3.6%) and The iShares Micro-Cap ETF (IWC) also jumped +4.33% closing at $124.24. Interestingly, along with the positive moves in the market, The VIX volatility index, the markets ‘fear gauge’, closed at $15.79, up 7.78% over the last 5-days.

Federal Reserve Rate Cut Expectations

Anticipation for potential interest rate cuts dominated market sentiment, with investors pricing in a 60% probability of a 25 basis point cut in September. The Fed’s focus appears to be shifting from solely inflation concerns to a more balanced approach, considering both employment and economic growth. This potential policy shift comes as core inflation has declined for four consecutive months, reaching its lowest level since April 2021 at 3.2%.

Economic Indicators and Market Sentiment

Recent economic data painted a mixed picture, influencing market sentiment. Existing home sales increased by 1.3% in July, falling short of economists’ expectations. The labor market showed signs of softening, with jobless claims ticking up to 232,000. These indicators, along with the Atlanta Fed’s reduced real GDP outlook to 2%, contributed to investor caution. Despite these concerns, markets remained resilient, buoyed by expectations of potential rate cuts and a soft landing for the economy.

Sector Standouts and Stragglers

In a week that saw stocks partying like it’s 1999 (or at least 2021), the S&P 500 sectors played a game of “follow the leader,” with real estate emerging as the unexpected MVP. The real estate sector, typically as exciting as watching paint dry, suddenly became the life of the party, surging 3.6% faster than you can say “location, location, location”. It seems investors decided that bricks and mortar were the new black, perhaps inspired by a collective urge to redecorate after staring at the same four walls for years. Meanwhile, materials stocks (+2.4%) built on their success, consumer discretionary (+2.1%) splurged on gains, and industrials (+1.8%) manufactured some impressive returns. The energy sector, however, apparently didn’t get the memo about the party, stumbling .5% like it had one too many at the oil well. Overall, the equal-weighted S&P 500 jumped 2.1%, proving that in this market, almost everyone gets to wear a party hat.

Stock Market Superstars

In the stock market’s version of “America’s Got Talent,” several companies strutted their stuff on the financial catwalk for the week ending August 23, 2024. NVIDIA (NVDA) continued its AI-powered ascent, soaring higher than a caffeinated squirrel, with a jaw-dropping 7% gain. It seems investors can’t get enough of NVIDIA’s chips – and we’re not talking about the potato kind. Meanwhile, Starbucks (SBUX) perked up the markets, brewing a robust 3.5% increase. Apparently, the promise of pumpkin spice season was enough to send the stock into a frothy frenzy, not to mention the amazing news that CEO Laxman Narasimhan bowed out and Starbucks proceeded to tap in Chipotle’s (CMG) CEO Brian Niccol. Apple (AAPL) didn’t fall far from the tree either, with a crisp 2.5% rise. The tech giant proved once again that it’s the apple of Wall Street’s eye. Not to be outdone, Super Micro Computer (SMCI) lived up to its name, super-charging investor portfolios with a mind-boggling 15% weekly gain. It seems in this market, being “super” is the new black. As for Tesla (TSLA), it charged ahead with a 7% boost, proving that electric dreams can indeed become reality – at least for shareholders. In this dazzling display of financial acrobatics, these stocks reminded us that in the circus of Wall Street, there’s always room for another high-wire act.

VP Watchlist Updates

Lantern (LTRN) closed at $4.65, +9.93% over the last 5-days.  Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On August 9, announced operational highlights and financial results for the second quarter 2024, ending June 30, 2024 highlighting the following:

  •  Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development.
  • Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort.
  • Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma’s drug candidate LP-284, including claims covering the new molecular entity.
  • Phase 1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 40 patients dosed to-date.
  • Achieved significant advancement towards key milestone in the development of molecular diagnostic for use with drug candidate LP-184 in future oncology clinical trials to improve patient selection and stratification.
  • Launched strategic drug development collaboration leveraging our AI platform, RADR®, with Oregon Therapeutics to optimize the development of first-in-class drug candidate XCE853 – a potent inhibitor of cancer metabolism.
  • Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma focused on CNS and brain cancers advanced with initiating site selection and feasibility for a Phase 1B/Phase 2 trial in recurrent GBM with drug candidate, STAR-001.
  • Launched Webinar Wednesdays, a webinar series that focuses on the areas of artificial intelligence and oncology drug development with leading physicians, scientists and Lantern collaborators.
    Approximately $33.3 million in cash, cash equivalents, and marketable securities as of June 30, 2024.

On August 7, Lantern announced a significant advancement demonstrating the preclinical synergy of LP-184 with checkpoint inhibitors and the ability of LP-184 to resensitize tumors that have become non-responsive to Anti-PD1 therapies. The company will be presenting preliminary data from the recent work done in conjunction with Drs. Yong Du and Shiaw-Yih (Phoebus) Lin at MD Anderson at The Immuno-Oncology Summit 2024 in Philadelphia.

The data will be presented in the form of poster entitled, LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor Microenvironment, (assigned Poster # P17). The poster highlights the following key points:

  • LP-184 seems to potentiate anti-PD1 response in a mouse model of TNBC that is non-hypermutated and resistant to immunotherapy in the absence of LP-184.

  • LP-184 can potentially transform immunologically “cold” tumors (non-responsive to IO therapies) into “hot” tumors (responsive to IO therapies) by modulating T cell activity in the tumor microenvironment and inducing a replication stress response defect.1

  • LP-184 seems to reshape the tumor microenvironment (TME) by significantly reducing the amount of M2 macrophages – which are associated with tumor drug resistance, tumor cell proliferation and are involved in helping the tumor cells escape immune cell death2.

  • LP-184 combined with an anti-PD1 agent elicited a greater anti-tumor response than monotherapies in mouse TNBC tumors that are non-hypermutated and resistant to immune checkpoint inhibitors

LP-184 is being investigated in an ongoing first-in-human Phase 1 trial (NCT05933265) in advanced recurrent solid tumors to establish a maximum tolerated dose and assess its overall safety and suitability in more targeted cancer indications, including TNBC.

Immunotherapy with checkpoint inhibitors (CPI) account for nearly $48 billion in sales annually according to Grand View Research and has profoundly changed the landscape of treatment in oncology since their introduction by providing outstanding durable responses and potential long-term remission in a significant proportion of cancer patients.3 Treatments are now approved for more than thirty cancer indications including melanoma, lung, colon, renal, urothelial, gastric, liver, lymphoma, head and neck but only a minority of patients benefit (10% to 50% depending on the stage and site of the tumor) and often patients will be non-responsive to CPI.

“Our drug-candidate, LP-184 has shown very promising preclinical evidence supporting its role in immuno-oncology to help patients improve response and durability of response to IO therapies. This work in collaboration with MD-Anderson supports our initial AI-driven hypothesis regarding the role of LP-184 to synergize with PD1 and PDL1 drugs and potentially improve the lives of a greater number of cancer patients globally. We look forward to developing combination drug studies and clinical trials with LP-184 and checkpoint inhibitors,” said Lantern Chief Scientific Officer, Kishor Bhatia, PhD, FRCP.

The entirety of the data and poster to be presented at The Immuno-Oncology Summit 2024 in Philadelphia will be available on the Lantern website after 6pm Eastern today, August 7th 2024.

On August 5, Lantern Pharma announced promising preliminary results from its Phase 2 HARMONIC™ clinical trial, evaluating LP-300 in combination with standard chemotherapy for never-smokers with advanced non-small cell lung cancer (NSCLC). As reported earlier today, August 5, the study has shown an impressive 86% clinical benefit rate in the initial patient group, offering hope for a patient population with limited treatment options. The proportion of never-smoking patients with non-small cell lung cancer (NSCLC) has been significantly increasing globally over the past 30 years, from 15% in the 1970s to 33% in the 2000s. The high proportion of never smokers with NSCLC in East Asian countries is of particular note with Japan estimated to be 33 to 40% of new cases and Taiwan at over 50% of new cases. Lantern has received regulatory approval to initiate the LP-300 clinical trial in multiple Asian countries, and has started activation of sites in Japan and Taiwan, including the National Cancer Center in Tokyo, a globally recognized center of cancer research excellence. Read the balance of the story. 

Panna Sharma, CEO of Lantern Pharma was interviewed recently on the ‘Today In Nashville’, a program hosted by Carole Sullivan and associated with Nashville’s WSMV 4, an NBC affiliate. Watch it here to learn more.


Eupraxia Pharmaceuticals (EPRX, $2.67, +4.71% over the last 5-days) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

On Aug. 7, Eupraxia announced its financial results for the second quarter of 2024. Dr. James Helliwell, CEO of Eupraxia stated, “Our eosinophilic esophagitis (“EoE”) clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study continues to suggest that EP-104GI could represent a significant improvement over currently approved therapies for this debilitating condition. In addition, during the second quarter, we presented data at two medical meetings highlighting the potential of our candidate for the treatment of knee osteoarthritis (“OA”), EP-104IAR, which also holds the potential to advance the current standard of care in OA. “Looking ahead, we anticipate reporting new data from the fourth cohort of the RESOLVE study in the near term and we continue to engage prospective partners for possible licensing of the EP-10IAR program. We look forward to engaging with the U.S. Food and Drug Administration in the fourth quarter of 2024 on the EP-104GI program and potentially expanding our gastrointestinal trials into the U.S. With two clinical-stage assets each having the potential to represent a meaningful improvement over currently approved therapies, we believe Eupraxia remains well positioned to create shareholder value.” Learn more here. 

On Aug. 2, Eupraxia announced entry into a new C$12 million convertible debt facility. Under the Convertible Debt Facility, Yabema Capital Limited and other current Eupraxia shareholders (together, the “Lenders”) will make available for drawdown an aggregate amount of C$12 million for a period of 120 days following entry into the agreement. The decision to draw on the facility within 120 days of closing is at the discretion of Eupraxia and is subject to the full and final release of the SVB Facility (as defined below), originally agreed to on June 21, 2021. The aggregate unpaid principal amount and any accrued and unpaid interest thereon will be convertible at each individual lender’s discretion into Eupraxia common shares (the “Common Shares”), at a conversion price equal to C$4.84375 per Common Share. The conversion is further subject to certain threshold limitations with respect to each lender’s aggregate ownership of the Common Shares. “The new convertible debt facility provides an important source of additional funding from long term, supportive investors, and creates greater stability to Eupraxia’s cap structure as we continue to advance our clinical programs in eosinophilic esophagitis and osteoarthritis,” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. The Convertible Debt Facility is subject to final approval of the Toronto Stock Exchange.

 

Dr. James Helliwell, CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX)

On July 9, a Tribe Public CEO Presentation and Q&A Webinar Event titled Exploring The Rapid Rise Of Osteoarthritis”  was held with James A. Helliwell, MD, Director and Chief Executive Officer of Eupraxia Pharmaceuticals (NASDAQ: EPRX).  The event video can now be viewed at the Tribe Public YouTube Channel!


Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating EoE. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

On June 5, Eupraxia announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology (“EULAR”) European Congress of Rheumatology 2024 (the “Meeting”). The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024.

 
Modular Medical, Inc. (NASDAQ: MODD, $1.76, +3.53% over the last 5-days and up +69.23% over the last year), is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On Friday, August 9, our sister organization, Tribe Public (www.TribePublic.com), hosted a brief CEO Presentation and Q&A Webinar-based event with Jeb Besser, CEO of Modular Medical (NASDAQ: MODD). The event is titled “Diabetes Care Innovator Modular Medical Takes Next Steps” You may view the event video now that has been view over 6,ooo times  at this link.

 
On July 15, Modular Medical announced a proof-of-concept study with Gubra A/S (“Gubra”) in a high-fat, diet-induced obese (“DIO”) mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. “A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks,” commented Jeb Besser, Chief Executive Officer of Modular Medical. “These discontinuations appear to be due to a combination of tolerability, cost, and inconsistent efficacy. We suspect that short-acting peptides may mitigate many of these side effects and dosage swings by better modulating dosage, but these therapies have generally been abandoned as “too difficult to use” because they required multiple doses per day to be effective. We see the potential for such dosing regimes to be greatly simplified and even improved by the use of pump technology to provide both a basal dose and boluses to control hunger. Using Gubra’s gold-standard DIO mouse model, MODD will seek to determine whether an existing FDA approved, short-acting peptide delivered from a pump platform can provide a more personalized and more tolerable solution for patients who found long acting GLP-1 drugs too difficult to tolerate, while delivering comparable glycemic control and weight loss, specifically for people with type 2 diabetes and obesity.” Learn more here.

On June 3, Modular Medical announced that it was set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

On Feb. 21, Modular Medical announced the closing of its previously announced underwritten public offering (the “offering”) of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s Chief Executive Officer, and Morgan Frank, a member of the Company’s board of directors, and other existing institutional investors. Each share of common stock was sold at a price to the public of $1.10 per share. The gross proceeds to Modular Medical from this offering were approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. In addition, Modular Medical has granted the underwriters a 30-day option to purchase up to an additional 1,321,989 shares of common stock to cover over-allotments, if any.Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.

On Jan. 24, Modular Medical announced the issuance of U.S. Patent 11,817,197 B2 for the stream-lined pairing of a pump to a mobile device. Paul DiPerna, Chairman and CTO of Modular Medical, commented, “The issuance of this patent is just another step in our mission to use technology to rethink and simplify the adoption of and ability to live with pump technology for patients and caregivers. To address cybersecurity risks and the complexity of pairing multiple devices to talk between a phone and a pump, we added Near-Field Communication (NFC), whereby, just by bringing the phone close to our pump will create a secure connection making it much easier to develop, test and maintain. This patent protects our technology addressing pairing, and, most importantly, the downloading of patient data to allow clinicians to easier upload and review the patients data. The patient’s phone is not required, and a clinician can simply tap the pump to the phone or tablet to pull the data using Bluetooth from patient pumps. In a high-volume practice, such as a busy certified pump trainer’s office, the ability to pull data from several patients quickly is critical. Our patented technology addresses the ability to do this without the tedious step of powering on and pairing with a myriad of new Bluetooth devices. It also simplifies moving the configuration to a new reusable controller, when needed, without using an intermediate device.” Jeb Besser, Modular Medical’s CEO, commented, “Our family of patents, which includes both issued patents and pending applications, around our pump is an important part of our strategic value and market positioning, and we look forward to announcing further patent issuances in the future.”
 
On Jan. 19, Modular Medical announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance. “This is an exciting milestone for the Company, as we seek to change the diabetes market. Almost 30 years after the introduction of the first insulin pump, more than three quarters of those who could benefit from wearing a pump do not wear one. It is our belief that our simplified design will encourage many “almost-pumpers” to adopt technology to aid in their diabetes management, without the complexity and expense required by many of the current solutions,” said Paul DiPerna, Chairman and CTO of Modular Medical.
 
On Dec. 21, Modular Medical announced a collaboration agreement with Glooko, Inc., a global leader specializing in connected care and remote patient monitoring for diabetes. Integrating with Glooko will allow clinicians and patients to easily review insulin dosing data from the MODD1 pump, when commercially available. In addition, through Glooko’s platform, Dexcom CGMS users will be able to view their glucose levels in the same accessible format in conjunction with their pump data. Glooko’s platform has a broad installed base, which has been deployed in over 30 countries and 8,000 clinical locations. Jeb Besser, CEO of Modular Medical stated, “We are extremely pleased to add the Glooko technology platform to our diabetes care system making it even easier and more cost effective for us to provide this important capability to our clinical and patient base. Glooko’s mission to improve health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform fits perfectly with our vision of providing an easy to use, affordable delivery technology to give more patients access to better care.”
 
 

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, closed at  $1.63, -1.21% over the last 5-days. Click to watch a brief video on Indaptus Therapeutics’ Decoy20 Cancer Treatment Approach.

On August 8, Indaptus announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,643,837 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,643,837 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.825. The warrants will have an exercise price of $1.70 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about August 8, 2024, subject to the satisfaction of customary closing conditions. Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering. The gross proceeds to Indaptus from the offering are expected to be approximately $3.0 million, before deducting the placement agent’s fees and other offering expenses payable by Indaptus. Indaptus intends to use the net proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.

On June 4, Indaptus announced that it will present a poster titled, “Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors,” at the American Society of Clinical Oncology annual meeting on June 1, 2024, in Chicago.

On May 22, Indaptus announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer immunotherapy that has first-in-class potential across a diverse range of cancers including liver, pancreatic, colorectal and non-small cell lung. Following review by a Safety Review Committee (SRC) of the company’s initial clinical data, which will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), the Company has successfully dosed the first patient in the multi-dose portion of the trial with Decoy20. The primary goal of this stage of the trial is to determine the safety of Decoy20 when administered multiple times to the same patient, and to begin to examine efficacy across multiple types of cancer. Decoy20 is composed of attenuated and killed, intact, non-pathogenic Gram-negative bacteria which are designed to act as a “decoy,” tricking the body into activating a broad antitumor response from both its innate and adaptive immune systems. In preclinical studies, the treatment has been shown to activate specialized immune receptors called TLRs, that facilitate a potent defense against tumors, without inducing excessive toxicity. The product candidate is designed to induce a strong and broad pulse of immune activation, followed by rapid clearance from the body.“Current immunotherapies usually target a few immune system pathways and have low cure rates in advanced cancers. Indaptus is investigating an incredibly exciting and differentiated approach to fighting cancerous tumors that deviates from a focus on targeted therapies in the field. The advancement of this trial is a significant milestone that builds on strong evidence that Decoy20 successfully and broadly activates potent tumor-fighting cytokines and chemokines in both the innate and adaptive immune systems, and was administered systemically without intolerable adverse events,”stated Roger Waltzman, MD, Chief Medical Officer of Indaptus.

 

Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $7.49, +.13% over the last 5-days and +9.68% YTD.

On Aug. 1, ADT reported its second quarter results for 2024 that read like a thrilling spy novel, complete with mysterious numbers and covert operations. The company reported a 3% increase in total revenue, reaching $1.2 billion – apparently, securing homes is more lucrative than ever in our paranoid future. Their recurring monthly revenue (RMR) grew by 2% to $355 million, proving that once ADT gets its foot in your door, it’s there to stay

The company boasted “strong customer retention” with a gross revenue attrition of 12.9%, which in ADT speak means they’re only hemorrhaging about 1 in 8 customers. Their “revenue payback” sits at 2.2 years, suggesting it takes that long for customers to stop regretting their decision to sign up.

In a plot twist worthy of a summer blockbuster, ADT’s GAAP income from continuing operations dropped by $54 million. But fear not, shareholders! Their “adjusted” income increased by $3 million. It seems ADT has mastered the art of financial alchemy, turning red numbers green faster than you can say “creative accounting”.

CEO Jim DeVries, channeling his inner motivational speaker, declared that ADT’s success is “powered by our employees’ dedication to the proposition that every second counts.” One can only imagine the intense pressure of working in an environment where bathroom breaks are timed to the millisecond.

 

CalEthos, Inc. (GEDC, $5.75, +47.44% over the last month), a developer of sustainable data center solutions, announced recently the following business update:

On July 24, 2024, CalEthos signed an Option Agreement to purchase 315 acres of land in the soon-to-be approved “Manufacturing Zone” of Lithium Valley. The new property provides CalEthos with significant advantages over its previous data center development site, which include:

  • Larger, strategically located, industrial-zoned property with acreage for on-site switchyard, substation and additional data center buildings

  • Better options for connectivity to high-voltage transmission lines

  • Closer proximity to existing and planned geothermal power plants

  • Shorter fiber routing distances to internet backbone and communications networks

  • Directly on the main north/south transportation corridor (Hwy. 111) and gateway entrance (Sinclair Rd.) to the planned 51,000-acre Lithium Valley development area

  • Lower flood risk – outside of the 100- and 500- year flood zones in a FEMA X (Unshaded) area 

CalEthos’ first of three development phases on the property is a planned 100-acre/420-megawatt (MW) campus, with up to 1,000,000 square feet of clean energy powered build-to-suit data centers to support AI, Cloud and Hyperscale customers.

“This new property gives CalEthos the acreage to develop 3 to 4 million square feet of data center over time as more geothermal power plants and other renewable energy and storage solutions come online in and around Lithium Valley”, said Joel Stone, the Company’s President and Chief Operating Officer.

CalEthos has been working over the last couple of years with the County of Imperial, Imperial Valley Economic Development Corp. (IVEDC), Imperial Irrigation District (IID), and geothermal power producers to develop a comprehensive plan that leverages the region’s clean energy resources to support a large-scale data center operation.

“CalEthos has the county’s full support to develop its data centers in alignment with the broader vision for Lithium Valley,” said Chairman Luis A. Plancarte, Imperial County Board of Supervisors. “The sooner CalEthos builds its data centers and utilizes locally produced power for their operations, the sooner our geothermal power producers can expand operations and increase lithium recovery.”

“CalEthos’ energy needs advance the building of additional local transmission, supports adding more sources of clean energy to the grid, and expedites plans for new geothermal power plants, without waiting for new long-distance transmission lines to be built to get power in and out of the area,” added Alex Cardenas, Chairman of IID.

Sean Wilcock, Vice President of IVEDC, emphasized the project’s positive economic impact, stating, “CalEthos’ data center plans accelerate Lithium Valley’s development by providing energy offtake opportunities, creates jobs, and stimulates the local economy. This project is a vital component of the long-term vision for the region and is a testament that Imperial County has the attributes necessary for the green data center industry.”

 

 

QUOTE OF WEEK

“People are not disturbed by things, but by the view they take of them.” – Epictetus

Investing & Inspiration

  1. “People are not disturbed by things, but by the view they take of them.” – Epictetus
  2. “Have patience. All things are difficult before they become easy.” – Saadi
  3. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  4. “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
  5. “The only true wisdom is in knowing you know nothing.” – Socrates
  6. “Courage is knowing what not to fear.”– Plato
  7. “The home is the chief school of human virtues.” – William Ellery Channing
  8. “Be brave. Take risks. Nothing can substitute experience.” – Paulo Coelho
  9. “There are no shortcuts in evolution.” – Louis D. Brandeis
  10. “A friend may well be reckoned the masterpiece of nature.” –  Ralph Waldo Emerson
  11. “Nature uses as little as possible of anything.” – Johannes Kepler
  12. “Every new beginning comes from some other beginning’s end.” – Seneca
  13. “Nothing ever becomes real till it is experienced.” – John Keats
  14. “Nobody who ever gave his best regretted it.” – George Halas
  15. “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
  16. “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
  17. “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
  18. “The secret of happiness is something to do.” – John Burroughs
  19. “The world of reality has its limits; the world of imagination is boundless.”
  20. “You begin with the possibilities of the material.” – Robert Rauschenberg
  21. “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
  22. “Leadership is the capacity to translate vision into reality.” – Warren Bennis
  23. “A man should always consider how much he has more than he wants.” – Joseph Addison
  24. “Happiness is good health and a bad memory.” –  Ingrid Bergman
  25. “We pass through this world but once.” – Stephen Jay Gould
  26. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
  27. “Nothing can have value without being an object of utility.” – Karl Marx
  28. “Always turn a negative situation into a positive situation.” – Michael Jordan
  29. “Courage is found in unlikely places.” – J. R. R. Tolkien
  30. “One that would have the fruit must climb the tree.” – Thomas Fuller
  31. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
  32. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
  33. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
  34. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
  35. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
  36. “Time is money.” – Benjamin Franklin
  37. “Change before you have to.” – Jack Welch
  38. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
  39. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
  40. “Care and diligence bring luck.” – Thomas Fuller
  41. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  42. “A man who is a master of patience is master of everything else.” – George Savile
  43. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  44. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
  45. “Act as if what you do makes a difference. It does.” – William James
  46. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  47. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  48. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  49. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  50. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  51. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  52. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  53. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  54. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  55. “Action is the foundational key to all success.” – Pablo Picasso
  56. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  57. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  58. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  59. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  60. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  61. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  62. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  63. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  64. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  65. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  66. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  67. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  68. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  69. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  70. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  71. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  72. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  73. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  74. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  75. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  76. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  77. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  78. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  79. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  80. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  81. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  82. “I want to put a ding in the universe.” – Steve Jobs

  83. “Research is creating new knowledge.” – Neil Armstrong

  84. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  85. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  86. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  87. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  88. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  89. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  90. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  91. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  92. “The best way out is always through.” – Robert Frost

  93. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  94. “Without labor nothing prospers.” – Sophocles

  95. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  96. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  97. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  98. “He who is brave is free.” – Lucius Annaeus Seneca
  99. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  100. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  101. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  102. “He who knows that enough is enough will always have enough.” – Lao Tzu

  103. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  104. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  105. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  106. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  107. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  108. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  109. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  110. “Success is dependent on effort.” – Sophocles
  111. “Nobody who ever gave his best regretted it.” – George Halas
  112. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  113. “And when I breathed, my breath was lightning.” – Black Elk
  114. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  115. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  116. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  117. “We are an impossibility in an impossible universe.” – Ray Bradbury
  118. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  119. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  120. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  121. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  122. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  123. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  124. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  125. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  126. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  127. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  128. “There is more to life than increasing its speed.” – Mahatma Gandhi
  129. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  130. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  131. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  132. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  133. “Life is too short for long-term grudges.” – Elon Musk
  134. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  135. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  136. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  137. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  138. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  139. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  140. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  141. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  142. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  143. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  144. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  145. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  146. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  147. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  148. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  149. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  150. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  151. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  152. “Delete the negative; accentuate the positive!” – Donna Karan
  153. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  154. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  155. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  156. “Everything has beauty, but not everyone sees it.” – Confucius
  157. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  158. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  159. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  160. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  161. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  162. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  163. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  164. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  165. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  166. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  167. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  168. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  169. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  170. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  171. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  172. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  173. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  174. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  175. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  176. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  177. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  178. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  179. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  180. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  181. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  182. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  183. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  184. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  185. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  186. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  187. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  188. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  189. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  190. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  191. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  192. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  193. “The secret of getting ahead is getting started.” – Mark Twain
  194. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe


Post View Count : 501